[Polychemotherapy treatment with cisplatin, adriamycin, 5-fluorouracil (FAP) and cisplatin, adriamycin and cyclophosphamide (CISCA) in advanced transitional carcinoma of the bladder].
We study 50 patients with advanced bladder carcinoma, divided into two protocols of 25 patients, treated with polychemotherapy. Protocol I (PAF) formed by DDP at 20 mgrs/m2 day 1 to 5, ADM at 50 mgrs./m2 day 1 and 5-FU at 500 mgrs./m2 day 1, and Protocol II (CISCA) made up of the combination of DDP at 75 mgrs./m2 day 1, ADM at 50 mgrs./2 day 1 and CPM at 600 mgrs./m2 I.V. day 1. In Protocol I the overall response was 60% (RC = 28%, RP = 32%), with amean response duration of 12.24 months, after receiving an average of 4.8 cycles. In Protocol II the results were 60% (RC = 16%, RP = 44%), 7.04 months and 5 cycles per patient, respectively. Both protocols were tolerated well, although Protcol I proved more toxic. Nauseas, vomiting and alopecia were the most common symptoms. There was no significant difference between the survival of responders and non-responders with Protocol I, but there was with Protocol II with (p less than 0.01).
Sánchez Romero
J A
JA
Ramírez Ruiz
F
F
Romero Fernández
L
L
Pastor Gaitán
P
P
Murillo Capitán
E
E
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004341:Drug Evaluation; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology
D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin; D005472:Fluorouracil
Tratamiento poliquimioterápico con cisplatino, adriamicina, 5-fluoracilo (PAF) y cisplatino, adriamicina y ciclofosfamida (CISCA) en el carcinoma transicional avanzado de vejiga.